Lv71
3240 积分 2023-10-10 加入
First-Line Therapy For Advanced Non-Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
3小时前
待确认
Re: First-line Therapy for Advanced Non–Clear Cell Renal Cell Carcinoma. A Systematic Review and Meta-analysis
3小时前
已关闭
Systemic therapy for non–clear cell renal cell carcinomas: A systematic review
3小时前
待确认
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
5天前
已完结
Pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression in patients with HER2-positive metastatic breast cancer (MBC) - The PERNETTA trial (SAKK 22/10), a randomized open label phase II study (SAKK, UNICANCER, BOOG)
1个月前
已关闭
Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia
1个月前
已完结
Artificial Intelligence–Powered Assessment of Pathologic Response to Neoadjuvant Atezolizumab in Patients With NSCLC: Results From the LCMC3 Study
9个月前
已完结
Applications of Artificial Intelligence in Lung Pathology
9个月前
已完结
Generative AI and large language models in nuclear medicine: current status and future prospects
9个月前
已完结
Comparison of Cabozantinib and Axitinib as Second-line Therapy After Nivolumab Plus Ipilimumab in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Comparative Analysis of Retrospective Real-world Data
9个月前
已完结
皖公网安备34019202002308
